Twist Bioscience Corporation Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Twist Bioscience Corporation (TWST) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 1.00% for the 12-month period ending 2021-09-30, per its 10-K filed 2021-11-23.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2021-11-23
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 1.00%, a 23.08% decline from fiscal 2020.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2020 was 1.30%, a 51.85% decline from fiscal 2019.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2019 was 2.70%, a 0.00% change from fiscal 2018.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2018 was 2.70%, a 33.66% increase from fiscal 2017.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|
| 2021-09-30 | 1.00% 10-K · filed 2021-11-23 | |
| 2020-09-30 | 1.30% 10-K · filed 2021-11-23 | |
| 2019-09-30 | 2.70% 10-K · filed 2021-11-23 | 2.72% 10-K · filed 2019-12-13 |
| 2018-09-30 | 2.70% 10-K · filed 2020-11-27 | 2.65% 10-K · filed 2019-12-13 |
| 2017-09-30 | 2.02% 10-K · filed 2019-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |